While SAGES is a strong event, and an inaugural one for Titan, I don't believe it is going to drive a strong increase in PPS. This morning they reported 2500 attendees at the show, in all reality, the physicians who attend events like these are typically aware of industry advancements. I wonder how many attendees were aware of Titan's progress in developing a functioning system prior to coming to the show? Would simply seeing the system in demonstration spur an increase in investment? Does the active system demonstration at SAGES just validate what the Titan headlines have already stated? I ask these questions out of true curiosity.. I do know the publicity of the event will bode very well for Titan; it will be interesting to see how that translates into PPS.
I'm not as intelligent on the investing side of this holding as some others on the board are, but I do know the medical space very well. SAGES is a major validation step for Titan. They are now more "real" in the eyes of a prestigious medical community subset. It is my opinion that the major drive of PPS will be once they enter human trials and start through the 510K process.
I am very excited for the next year of being involved with this company as a shareholder. The past 3 years have been boringly filled with anxiety.
News 
Market Data 
Discover 
